Epigenetics In Ophthalmology

Epigenetics relies on the modification of gene expression induced by changes in the environment without altering DNA structure. The most common epigenetic changes include DNA and mRNA methylation and crosstalk between histone and non-histone modifications, and regulatory non-coding RNA molecules, primarily microRNAs (miRNAs). In ophthalmology, epigenetics is an emerging field that has opened new avenues to improve our understanding of the molecular basis of eye physiological development. It has also enhanced our understanding of the pathogenesis of ocular disease. Many eye diseases have complex etiologies, and epigenetic changes now known to be associated with ocular disease include DNA methylation, histone and non-histone post-translational modifications, and non-coding RNA regulators. These genetic modifications are dynamic and act through different mechanisms. Determining how, where and when specific epigenetic changes trigger ocular diseases could provide useful clinical biomarkers for prevention, diagnosis and management, as well as targets for innovative drugs.

Fig. 1. Epigenome: the bridge between environment and genome in ocular disease pathobiology. (Lanza M, et al., 2019)

Our Services

A comprehensive ophthalmology solutions company, Ace Therapeutics is dedicated to the discovery and analysis of potential biomarkers in relevant samples through epigenomics. This includes tears, vitreous humor, aqueous humor, retina, serum, plasma, and other biological fluids.

Ace Therapeutics' consulting scientists are well versed in epigenetic mechanisms, including DNA methylation, histone modifications, and microRNA expression. They are also well versed in their potential modification through exposure to a variety of pharmaceutical, food, consumer product, and environmental compounds. Our consulting scientists have extensive experience of analyzing and interpreting genetic data. They have a deep understanding of epigenetic mechanisms related to ocular biomarkers, which can help clients identify potential biomarkers more quickly, and design and develop individual bespoke projects.

Ace Therapeutics research team has rich experience in bioinformatics analysis and provides one-stop services from sample pre-processing to data post-analysis.

The Goals of Ace Therapeutics

Using a range of cutting-edge epigenetic techniques combined with informatics to identify the genetic and environmental determinants of common and complex eye diseases.

• Ocular epigenetic regulators: Elucidating molecular mechanisms associated with mutated epigenetic regulators in eye diseases
• Chromatin signaling in the eye: Defining enhancers and transcriptional programming imposed through aberrant signaling cascades in ocular diseases, identifying and elucidating the functions and potential biomarkers of key epigenetic targets of aberrant growth signaling in ocular diseases.
• Ocular translational epigenetics: Validation of epigenetic targets for therapeutic interventions and biomarker development in preclinical studies to launch personalized ocular epigenetic biomarkers and therapies.

Experimental Design

• Provide in vitro studies that generate the high-quality DNA/RNA required for epigenetic analysis.
• Quantitative PCR for gene-specific analysis (methylation specific, single miRNA, post-ChIP)
• Microarray technology for genome-wide analysis
• ATAC-seq, DNase-seq, ChIP-seq, FAIRE-seq, MeDIP-seq, Small-RNA-seq for next-generation sequencing
• High-throughput screening analysis
• Experiments to anchor epigenetic alterations to functional endpoints (e.g. gene and/or protein expression, genotoxicity, phenotypic outcome).

Our Advantages

• Rich experience in epigenetics and biomarker analysis.
• Unique comprehensive service for ocular biomarker research.
• Excellent research team.
• Comprehensive research platforms.

Our goal at Ace Therapeutics is to provide the most professional service to our global customers. Our scientists are always ready to provide high-quality epigenomic-based ocular biomarkers discovery and analysis solutions for global customers. If you have questions about the content of this service, please feel free to contact us. We look forward to hearing from you.

Reference

1. Lanza M, Benincasa G, Costa D, et al. Clinical Role of Epigenetics and Network Analysis in Eye Diseases: A Translational Science Review. J Ophthalmol. 2019;2019:2424956.

• Proteomic-Based Ocular Biomarker Discovery and Analysis Services
• Genomics-Based Ocular Biomarker Discovery and Analysis Services
• Metabolomics-Based Ocular Biomarker Discovery and Analysis Services
• Lipidomics-Based Ocular Biomarker Discovery and Analysis Services
• Ocular Cell Biomarker Discovery and Analysis Services
• Ocular Tissue Biomarker Discovery and Analysis Services

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit